Medical Care
Global Oral Anti-diabetes Drugs Market Research Report 2025
- Jul 08, 25
- ID: 348820
- Pages: 96
- Figures: 92
- Views: 16
The global market for Oral Anti-diabetes Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Diabetes is a chronic disease that occurs when the body cannot effectively use the produced insulin or the pancreas does not produce sufficient insulin. The pancreas is an organ that sits behind the stomach and releases hormones into the digestive system. Diabetes is categorized by increased levels of blood glucose, which can cause severe damage to blood vessels, heart, kidneys, nerves, and eyes. Diabetes is also called hyperglycemia or raised blood sugar. Insulin is a hormone that regulates the blood sugar level in body. Continuous increase in blood sugar leads to diabetes. Uncontrollable diabetes can damage the nervous system and other body systems. Diabetes is of two types: type 1 and type 2. Type 1 diabetes, also known as juvenile diabetes or insulin-dependent diabetes, arises when the immune system misguidedly attacks and kills the beta cells of the pancreas. In type 1 diabetes, little or no insulin is released into the body, owing to this sugar builds up in the blood instead of being used as energy. Type 1 diabetes is rare, and only 10% of people with diabetes have type 1 diabetes. It commonly occurs in childhood or adolescence. Type 2 diabetes arises when the body cannot appropriately use the insulin that is released or does not make enough insulin. As a consequence, sugar builds up in the blood instead of being used as energy. About 90% of people with diabetes have type 2 diabetes.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oral Anti-diabetes Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Anti-diabetes Drugs.
The Oral Anti-diabetes Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oral Anti-diabetes Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Anti-diabetes Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
Eli Lilly
AstraZeneca plc
Astellas Pharma Inc
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Merck
Takeda
Bristol Myers Squibb
Novartis
Pfizer
Abbott
Biocon
Sunpharma
Novo Nordisk
Piramal Healthcare
Bayer Healthcare
Dr. Reddy’s Laboratories Ltd
Glenmark Pharmaceuticals Ltd
Segment by Type
by Type
by Drug Class
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oral Anti-diabetes Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Diabetes is a chronic disease that occurs when the body cannot effectively use the produced insulin or the pancreas does not produce sufficient insulin. The pancreas is an organ that sits behind the stomach and releases hormones into the digestive system. Diabetes is categorized by increased levels of blood glucose, which can cause severe damage to blood vessels, heart, kidneys, nerves, and eyes. Diabetes is also called hyperglycemia or raised blood sugar. Insulin is a hormone that regulates the blood sugar level in body. Continuous increase in blood sugar leads to diabetes. Uncontrollable diabetes can damage the nervous system and other body systems. Diabetes is of two types: type 1 and type 2. Type 1 diabetes, also known as juvenile diabetes or insulin-dependent diabetes, arises when the immune system misguidedly attacks and kills the beta cells of the pancreas. In type 1 diabetes, little or no insulin is released into the body, owing to this sugar builds up in the blood instead of being used as energy. Type 1 diabetes is rare, and only 10% of people with diabetes have type 1 diabetes. It commonly occurs in childhood or adolescence. Type 2 diabetes arises when the body cannot appropriately use the insulin that is released or does not make enough insulin. As a consequence, sugar builds up in the blood instead of being used as energy. About 90% of people with diabetes have type 2 diabetes.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oral Anti-diabetes Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Anti-diabetes Drugs.
The Oral Anti-diabetes Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oral Anti-diabetes Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Anti-diabetes Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
Eli Lilly
AstraZeneca plc
Astellas Pharma Inc
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Merck
Takeda
Bristol Myers Squibb
Novartis
Pfizer
Abbott
Biocon
Sunpharma
Novo Nordisk
Piramal Healthcare
Bayer Healthcare
Dr. Reddy’s Laboratories Ltd
Glenmark Pharmaceuticals Ltd
Segment by Type
by Type
by Drug Class
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oral Anti-diabetes Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oral Anti-diabetes Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 by Type
1.2.3 by Drug Class
1.3 Market by Application
1.3.1 Global Oral Anti-diabetes Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oral Anti-diabetes Drugs Market Perspective (2020-2031)
2.2 Global Oral Anti-diabetes Drugs Growth Trends by Region
2.2.1 Global Oral Anti-diabetes Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Oral Anti-diabetes Drugs Historic Market Size by Region (2020-2025)
2.2.3 Oral Anti-diabetes Drugs Forecasted Market Size by Region (2026-2031)
2.3 Oral Anti-diabetes Drugs Market Dynamics
2.3.1 Oral Anti-diabetes Drugs Industry Trends
2.3.2 Oral Anti-diabetes Drugs Market Drivers
2.3.3 Oral Anti-diabetes Drugs Market Challenges
2.3.4 Oral Anti-diabetes Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oral Anti-diabetes Drugs Players by Revenue
3.1.1 Global Top Oral Anti-diabetes Drugs Players by Revenue (2020-2025)
3.1.2 Global Oral Anti-diabetes Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Oral Anti-diabetes Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oral Anti-diabetes Drugs Revenue
3.4 Global Oral Anti-diabetes Drugs Market Concentration Ratio
3.4.1 Global Oral Anti-diabetes Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oral Anti-diabetes Drugs Revenue in 2024
3.5 Global Key Players of Oral Anti-diabetes Drugs Head office and Area Served
3.6 Global Key Players of Oral Anti-diabetes Drugs, Product and Application
3.7 Global Key Players of Oral Anti-diabetes Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oral Anti-diabetes Drugs Breakdown Data by Type
4.1 Global Oral Anti-diabetes Drugs Historic Market Size by Type (2020-2025)
4.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2026-2031)
5 Oral Anti-diabetes Drugs Breakdown Data by Application
5.1 Global Oral Anti-diabetes Drugs Historic Market Size by Application (2020-2025)
5.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Oral Anti-diabetes Drugs Market Size (2020-2031)
6.2 North America Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Oral Anti-diabetes Drugs Market Size by Country (2020-2025)
6.4 North America Oral Anti-diabetes Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oral Anti-diabetes Drugs Market Size (2020-2031)
7.2 Europe Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Oral Anti-diabetes Drugs Market Size by Country (2020-2025)
7.4 Europe Oral Anti-diabetes Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size (2020-2031)
8.2 Asia-Pacific Oral Anti-diabetes Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oral Anti-diabetes Drugs Market Size (2020-2031)
9.2 Latin America Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Oral Anti-diabetes Drugs Market Size by Country (2020-2025)
9.4 Latin America Oral Anti-diabetes Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size (2020-2031)
10.2 Middle East & Africa Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Oral Anti-diabetes Drugs Introduction
11.1.4 Sanofi Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.1.5 Sanofi Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Oral Anti-diabetes Drugs Introduction
11.2.4 Eli Lilly Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.2.5 Eli Lilly Recent Development
11.3 AstraZeneca plc
11.3.1 AstraZeneca plc Company Details
11.3.2 AstraZeneca plc Business Overview
11.3.3 AstraZeneca plc Oral Anti-diabetes Drugs Introduction
11.3.4 AstraZeneca plc Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.3.5 AstraZeneca plc Recent Development
11.4 Astellas Pharma Inc
11.4.1 Astellas Pharma Inc Company Details
11.4.2 Astellas Pharma Inc Business Overview
11.4.3 Astellas Pharma Inc Oral Anti-diabetes Drugs Introduction
11.4.4 Astellas Pharma Inc Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.4.5 Astellas Pharma Inc Recent Development
11.5 Johnson & Johnson (Janssen Pharmaceuticals)
11.5.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Details
11.5.2 Johnson & Johnson (Janssen Pharmaceuticals) Business Overview
11.5.3 Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Introduction
11.5.4 Johnson & Johnson (Janssen Pharmaceuticals) Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.5.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Oral Anti-diabetes Drugs Introduction
11.6.4 Boehringer Ingelheim Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Oral Anti-diabetes Drugs Introduction
11.7.4 Merck Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.7.5 Merck Recent Development
11.8 Takeda
11.8.1 Takeda Company Details
11.8.2 Takeda Business Overview
11.8.3 Takeda Oral Anti-diabetes Drugs Introduction
11.8.4 Takeda Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.8.5 Takeda Recent Development
11.9 Bristol Myers Squibb
11.9.1 Bristol Myers Squibb Company Details
11.9.2 Bristol Myers Squibb Business Overview
11.9.3 Bristol Myers Squibb Oral Anti-diabetes Drugs Introduction
11.9.4 Bristol Myers Squibb Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.9.5 Bristol Myers Squibb Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Oral Anti-diabetes Drugs Introduction
11.10.4 Novartis Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.10.5 Novartis Recent Development
11.11 Pfizer
11.11.1 Pfizer Company Details
11.11.2 Pfizer Business Overview
11.11.3 Pfizer Oral Anti-diabetes Drugs Introduction
11.11.4 Pfizer Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.11.5 Pfizer Recent Development
11.12 Abbott
11.12.1 Abbott Company Details
11.12.2 Abbott Business Overview
11.12.3 Abbott Oral Anti-diabetes Drugs Introduction
11.12.4 Abbott Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.12.5 Abbott Recent Development
11.13 Biocon
11.13.1 Biocon Company Details
11.13.2 Biocon Business Overview
11.13.3 Biocon Oral Anti-diabetes Drugs Introduction
11.13.4 Biocon Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.13.5 Biocon Recent Development
11.14 Sunpharma
11.14.1 Sunpharma Company Details
11.14.2 Sunpharma Business Overview
11.14.3 Sunpharma Oral Anti-diabetes Drugs Introduction
11.14.4 Sunpharma Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.14.5 Sunpharma Recent Development
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Details
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Oral Anti-diabetes Drugs Introduction
11.15.4 Novo Nordisk Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.15.5 Novo Nordisk Recent Development
11.16 Piramal Healthcare
11.16.1 Piramal Healthcare Company Details
11.16.2 Piramal Healthcare Business Overview
11.16.3 Piramal Healthcare Oral Anti-diabetes Drugs Introduction
11.16.4 Piramal Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.16.5 Piramal Healthcare Recent Development
11.17 Bayer Healthcare
11.17.1 Bayer Healthcare Company Details
11.17.2 Bayer Healthcare Business Overview
11.17.3 Bayer Healthcare Oral Anti-diabetes Drugs Introduction
11.17.4 Bayer Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.17.5 Bayer Healthcare Recent Development
11.18 Dr. Reddy’s Laboratories Ltd
11.18.1 Dr. Reddy’s Laboratories Ltd Company Details
11.18.2 Dr. Reddy’s Laboratories Ltd Business Overview
11.18.3 Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Introduction
11.18.4 Dr. Reddy’s Laboratories Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.18.5 Dr. Reddy’s Laboratories Ltd Recent Development
11.19 Glenmark Pharmaceuticals Ltd
11.19.1 Glenmark Pharmaceuticals Ltd Company Details
11.19.2 Glenmark Pharmaceuticals Ltd Business Overview
11.19.3 Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Introduction
11.19.4 Glenmark Pharmaceuticals Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.19.5 Glenmark Pharmaceuticals Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oral Anti-diabetes Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 by Type
1.2.3 by Drug Class
1.3 Market by Application
1.3.1 Global Oral Anti-diabetes Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oral Anti-diabetes Drugs Market Perspective (2020-2031)
2.2 Global Oral Anti-diabetes Drugs Growth Trends by Region
2.2.1 Global Oral Anti-diabetes Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Oral Anti-diabetes Drugs Historic Market Size by Region (2020-2025)
2.2.3 Oral Anti-diabetes Drugs Forecasted Market Size by Region (2026-2031)
2.3 Oral Anti-diabetes Drugs Market Dynamics
2.3.1 Oral Anti-diabetes Drugs Industry Trends
2.3.2 Oral Anti-diabetes Drugs Market Drivers
2.3.3 Oral Anti-diabetes Drugs Market Challenges
2.3.4 Oral Anti-diabetes Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oral Anti-diabetes Drugs Players by Revenue
3.1.1 Global Top Oral Anti-diabetes Drugs Players by Revenue (2020-2025)
3.1.2 Global Oral Anti-diabetes Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Oral Anti-diabetes Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oral Anti-diabetes Drugs Revenue
3.4 Global Oral Anti-diabetes Drugs Market Concentration Ratio
3.4.1 Global Oral Anti-diabetes Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oral Anti-diabetes Drugs Revenue in 2024
3.5 Global Key Players of Oral Anti-diabetes Drugs Head office and Area Served
3.6 Global Key Players of Oral Anti-diabetes Drugs, Product and Application
3.7 Global Key Players of Oral Anti-diabetes Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oral Anti-diabetes Drugs Breakdown Data by Type
4.1 Global Oral Anti-diabetes Drugs Historic Market Size by Type (2020-2025)
4.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2026-2031)
5 Oral Anti-diabetes Drugs Breakdown Data by Application
5.1 Global Oral Anti-diabetes Drugs Historic Market Size by Application (2020-2025)
5.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Oral Anti-diabetes Drugs Market Size (2020-2031)
6.2 North America Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Oral Anti-diabetes Drugs Market Size by Country (2020-2025)
6.4 North America Oral Anti-diabetes Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oral Anti-diabetes Drugs Market Size (2020-2031)
7.2 Europe Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Oral Anti-diabetes Drugs Market Size by Country (2020-2025)
7.4 Europe Oral Anti-diabetes Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size (2020-2031)
8.2 Asia-Pacific Oral Anti-diabetes Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oral Anti-diabetes Drugs Market Size (2020-2031)
9.2 Latin America Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Oral Anti-diabetes Drugs Market Size by Country (2020-2025)
9.4 Latin America Oral Anti-diabetes Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size (2020-2031)
10.2 Middle East & Africa Oral Anti-diabetes Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Oral Anti-diabetes Drugs Introduction
11.1.4 Sanofi Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.1.5 Sanofi Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Oral Anti-diabetes Drugs Introduction
11.2.4 Eli Lilly Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.2.5 Eli Lilly Recent Development
11.3 AstraZeneca plc
11.3.1 AstraZeneca plc Company Details
11.3.2 AstraZeneca plc Business Overview
11.3.3 AstraZeneca plc Oral Anti-diabetes Drugs Introduction
11.3.4 AstraZeneca plc Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.3.5 AstraZeneca plc Recent Development
11.4 Astellas Pharma Inc
11.4.1 Astellas Pharma Inc Company Details
11.4.2 Astellas Pharma Inc Business Overview
11.4.3 Astellas Pharma Inc Oral Anti-diabetes Drugs Introduction
11.4.4 Astellas Pharma Inc Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.4.5 Astellas Pharma Inc Recent Development
11.5 Johnson & Johnson (Janssen Pharmaceuticals)
11.5.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Details
11.5.2 Johnson & Johnson (Janssen Pharmaceuticals) Business Overview
11.5.3 Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Introduction
11.5.4 Johnson & Johnson (Janssen Pharmaceuticals) Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.5.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Oral Anti-diabetes Drugs Introduction
11.6.4 Boehringer Ingelheim Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Oral Anti-diabetes Drugs Introduction
11.7.4 Merck Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.7.5 Merck Recent Development
11.8 Takeda
11.8.1 Takeda Company Details
11.8.2 Takeda Business Overview
11.8.3 Takeda Oral Anti-diabetes Drugs Introduction
11.8.4 Takeda Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.8.5 Takeda Recent Development
11.9 Bristol Myers Squibb
11.9.1 Bristol Myers Squibb Company Details
11.9.2 Bristol Myers Squibb Business Overview
11.9.3 Bristol Myers Squibb Oral Anti-diabetes Drugs Introduction
11.9.4 Bristol Myers Squibb Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.9.5 Bristol Myers Squibb Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Oral Anti-diabetes Drugs Introduction
11.10.4 Novartis Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.10.5 Novartis Recent Development
11.11 Pfizer
11.11.1 Pfizer Company Details
11.11.2 Pfizer Business Overview
11.11.3 Pfizer Oral Anti-diabetes Drugs Introduction
11.11.4 Pfizer Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.11.5 Pfizer Recent Development
11.12 Abbott
11.12.1 Abbott Company Details
11.12.2 Abbott Business Overview
11.12.3 Abbott Oral Anti-diabetes Drugs Introduction
11.12.4 Abbott Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.12.5 Abbott Recent Development
11.13 Biocon
11.13.1 Biocon Company Details
11.13.2 Biocon Business Overview
11.13.3 Biocon Oral Anti-diabetes Drugs Introduction
11.13.4 Biocon Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.13.5 Biocon Recent Development
11.14 Sunpharma
11.14.1 Sunpharma Company Details
11.14.2 Sunpharma Business Overview
11.14.3 Sunpharma Oral Anti-diabetes Drugs Introduction
11.14.4 Sunpharma Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.14.5 Sunpharma Recent Development
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Details
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Oral Anti-diabetes Drugs Introduction
11.15.4 Novo Nordisk Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.15.5 Novo Nordisk Recent Development
11.16 Piramal Healthcare
11.16.1 Piramal Healthcare Company Details
11.16.2 Piramal Healthcare Business Overview
11.16.3 Piramal Healthcare Oral Anti-diabetes Drugs Introduction
11.16.4 Piramal Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.16.5 Piramal Healthcare Recent Development
11.17 Bayer Healthcare
11.17.1 Bayer Healthcare Company Details
11.17.2 Bayer Healthcare Business Overview
11.17.3 Bayer Healthcare Oral Anti-diabetes Drugs Introduction
11.17.4 Bayer Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.17.5 Bayer Healthcare Recent Development
11.18 Dr. Reddy’s Laboratories Ltd
11.18.1 Dr. Reddy’s Laboratories Ltd Company Details
11.18.2 Dr. Reddy’s Laboratories Ltd Business Overview
11.18.3 Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Introduction
11.18.4 Dr. Reddy’s Laboratories Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.18.5 Dr. Reddy’s Laboratories Ltd Recent Development
11.19 Glenmark Pharmaceuticals Ltd
11.19.1 Glenmark Pharmaceuticals Ltd Company Details
11.19.2 Glenmark Pharmaceuticals Ltd Business Overview
11.19.3 Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Introduction
11.19.4 Glenmark Pharmaceuticals Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025)
11.19.5 Glenmark Pharmaceuticals Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Oral Anti-diabetes Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of by Type
Table 3. Key Players of by Drug Class
Table 4. Global Oral Anti-diabetes Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Oral Anti-diabetes Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Oral Anti-diabetes Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Oral Anti-diabetes Drugs Market Share by Region (2020-2025)
Table 8. Global Oral Anti-diabetes Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Oral Anti-diabetes Drugs Market Share by Region (2026-2031)
Table 10. Oral Anti-diabetes Drugs Market Trends
Table 11. Oral Anti-diabetes Drugs Market Drivers
Table 12. Oral Anti-diabetes Drugs Market Challenges
Table 13. Oral Anti-diabetes Drugs Market Restraints
Table 14. Global Oral Anti-diabetes Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Oral Anti-diabetes Drugs Market Share by Players (2020-2025)
Table 16. Global Top Oral Anti-diabetes Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Anti-diabetes Drugs as of 2024)
Table 17. Ranking of Global Top Oral Anti-diabetes Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Oral Anti-diabetes Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Oral Anti-diabetes Drugs, Headquarters and Area Served
Table 20. Global Key Players of Oral Anti-diabetes Drugs, Product and Application
Table 21. Global Key Players of Oral Anti-diabetes Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Oral Anti-diabetes Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Oral Anti-diabetes Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Oral Anti-diabetes Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Oral Anti-diabetes Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Oral Anti-diabetes Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Oral Anti-diabetes Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Oral Anti-diabetes Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Oral Anti-diabetes Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Sanofi Company Details
Table 47. Sanofi Business Overview
Table 48. Sanofi Oral Anti-diabetes Drugs Product
Table 49. Sanofi Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 50. Sanofi Recent Development
Table 51. Eli Lilly Company Details
Table 52. Eli Lilly Business Overview
Table 53. Eli Lilly Oral Anti-diabetes Drugs Product
Table 54. Eli Lilly Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 55. Eli Lilly Recent Development
Table 56. AstraZeneca plc Company Details
Table 57. AstraZeneca plc Business Overview
Table 58. AstraZeneca plc Oral Anti-diabetes Drugs Product
Table 59. AstraZeneca plc Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 60. AstraZeneca plc Recent Development
Table 61. Astellas Pharma Inc Company Details
Table 62. Astellas Pharma Inc Business Overview
Table 63. Astellas Pharma Inc Oral Anti-diabetes Drugs Product
Table 64. Astellas Pharma Inc Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 65. Astellas Pharma Inc Recent Development
Table 66. Johnson & Johnson (Janssen Pharmaceuticals) Company Details
Table 67. Johnson & Johnson (Janssen Pharmaceuticals) Business Overview
Table 68. Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Product
Table 69. Johnson & Johnson (Janssen Pharmaceuticals) Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 70. Johnson & Johnson (Janssen Pharmaceuticals) Recent Development
Table 71. Boehringer Ingelheim Company Details
Table 72. Boehringer Ingelheim Business Overview
Table 73. Boehringer Ingelheim Oral Anti-diabetes Drugs Product
Table 74. Boehringer Ingelheim Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 75. Boehringer Ingelheim Recent Development
Table 76. Merck Company Details
Table 77. Merck Business Overview
Table 78. Merck Oral Anti-diabetes Drugs Product
Table 79. Merck Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 80. Merck Recent Development
Table 81. Takeda Company Details
Table 82. Takeda Business Overview
Table 83. Takeda Oral Anti-diabetes Drugs Product
Table 84. Takeda Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 85. Takeda Recent Development
Table 86. Bristol Myers Squibb Company Details
Table 87. Bristol Myers Squibb Business Overview
Table 88. Bristol Myers Squibb Oral Anti-diabetes Drugs Product
Table 89. Bristol Myers Squibb Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 90. Bristol Myers Squibb Recent Development
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Oral Anti-diabetes Drugs Product
Table 94. Novartis Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 95. Novartis Recent Development
Table 96. Pfizer Company Details
Table 97. Pfizer Business Overview
Table 98. Pfizer Oral Anti-diabetes Drugs Product
Table 99. Pfizer Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 100. Pfizer Recent Development
Table 101. Abbott Company Details
Table 102. Abbott Business Overview
Table 103. Abbott Oral Anti-diabetes Drugs Product
Table 104. Abbott Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 105. Abbott Recent Development
Table 106. Biocon Company Details
Table 107. Biocon Business Overview
Table 108. Biocon Oral Anti-diabetes Drugs Product
Table 109. Biocon Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 110. Biocon Recent Development
Table 111. Sunpharma Company Details
Table 112. Sunpharma Business Overview
Table 113. Sunpharma Oral Anti-diabetes Drugs Product
Table 114. Sunpharma Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 115. Sunpharma Recent Development
Table 116. Novo Nordisk Company Details
Table 117. Novo Nordisk Business Overview
Table 118. Novo Nordisk Oral Anti-diabetes Drugs Product
Table 119. Novo Nordisk Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 120. Novo Nordisk Recent Development
Table 121. Piramal Healthcare Company Details
Table 122. Piramal Healthcare Business Overview
Table 123. Piramal Healthcare Oral Anti-diabetes Drugs Product
Table 124. Piramal Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 125. Piramal Healthcare Recent Development
Table 126. Bayer Healthcare Company Details
Table 127. Bayer Healthcare Business Overview
Table 128. Bayer Healthcare Oral Anti-diabetes Drugs Product
Table 129. Bayer Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 130. Bayer Healthcare Recent Development
Table 131. Dr. Reddy’s Laboratories Ltd Company Details
Table 132. Dr. Reddy’s Laboratories Ltd Business Overview
Table 133. Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Product
Table 134. Dr. Reddy’s Laboratories Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 135. Dr. Reddy’s Laboratories Ltd Recent Development
Table 136. Glenmark Pharmaceuticals Ltd Company Details
Table 137. Glenmark Pharmaceuticals Ltd Business Overview
Table 138. Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Product
Table 139. Glenmark Pharmaceuticals Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 140. Glenmark Pharmaceuticals Ltd Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
Table 144. Authors List of This Report
List of Figures
Figure 1. Oral Anti-diabetes Drugs Picture
Figure 2. Global Oral Anti-diabetes Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Oral Anti-diabetes Drugs Market Share by Type: 2024 VS 2031
Figure 4. by Type Features
Figure 5. by Drug Class Features
Figure 6. Global Oral Anti-diabetes Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Oral Anti-diabetes Drugs Market Share by Application: 2024 VS 2031
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. Oral Anti-diabetes Drugs Report Years Considered
Figure 12. Global Oral Anti-diabetes Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Oral Anti-diabetes Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Oral Anti-diabetes Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global Oral Anti-diabetes Drugs Market Share by Players in 2024
Figure 16. Global Top Oral Anti-diabetes Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Anti-diabetes Drugs as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Oral Anti-diabetes Drugs Revenue in 2024
Figure 18. North America Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Oral Anti-diabetes Drugs Market Share by Country (2020-2031)
Figure 20. United States Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Oral Anti-diabetes Drugs Market Share by Country (2020-2031)
Figure 24. Germany Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Oral Anti-diabetes Drugs Market Share by Region (2020-2031)
Figure 32. China Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Oral Anti-diabetes Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Oral Anti-diabetes Drugs Market Share by Country (2020-2031)
Figure 44. Turkey Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Sanofi Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 48. Eli Lilly Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 49. AstraZeneca plc Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 50. Astellas Pharma Inc Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 51. Johnson & Johnson (Janssen Pharmaceuticals) Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 52. Boehringer Ingelheim Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 53. Merck Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 54. Takeda Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 55. Bristol Myers Squibb Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 56. Novartis Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 57. Pfizer Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 58. Abbott Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 59. Biocon Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 60. Sunpharma Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 61. Novo Nordisk Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 62. Piramal Healthcare Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 63. Bayer Healthcare Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 64. Dr. Reddy’s Laboratories Ltd Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 65. Glenmark Pharmaceuticals Ltd Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Table 1. Global Oral Anti-diabetes Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of by Type
Table 3. Key Players of by Drug Class
Table 4. Global Oral Anti-diabetes Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Oral Anti-diabetes Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Oral Anti-diabetes Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Oral Anti-diabetes Drugs Market Share by Region (2020-2025)
Table 8. Global Oral Anti-diabetes Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Oral Anti-diabetes Drugs Market Share by Region (2026-2031)
Table 10. Oral Anti-diabetes Drugs Market Trends
Table 11. Oral Anti-diabetes Drugs Market Drivers
Table 12. Oral Anti-diabetes Drugs Market Challenges
Table 13. Oral Anti-diabetes Drugs Market Restraints
Table 14. Global Oral Anti-diabetes Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Oral Anti-diabetes Drugs Market Share by Players (2020-2025)
Table 16. Global Top Oral Anti-diabetes Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Anti-diabetes Drugs as of 2024)
Table 17. Ranking of Global Top Oral Anti-diabetes Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Oral Anti-diabetes Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Oral Anti-diabetes Drugs, Headquarters and Area Served
Table 20. Global Key Players of Oral Anti-diabetes Drugs, Product and Application
Table 21. Global Key Players of Oral Anti-diabetes Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Oral Anti-diabetes Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Oral Anti-diabetes Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Oral Anti-diabetes Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Oral Anti-diabetes Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Oral Anti-diabetes Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Oral Anti-diabetes Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Oral Anti-diabetes Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Oral Anti-diabetes Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Oral Anti-diabetes Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Sanofi Company Details
Table 47. Sanofi Business Overview
Table 48. Sanofi Oral Anti-diabetes Drugs Product
Table 49. Sanofi Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 50. Sanofi Recent Development
Table 51. Eli Lilly Company Details
Table 52. Eli Lilly Business Overview
Table 53. Eli Lilly Oral Anti-diabetes Drugs Product
Table 54. Eli Lilly Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 55. Eli Lilly Recent Development
Table 56. AstraZeneca plc Company Details
Table 57. AstraZeneca plc Business Overview
Table 58. AstraZeneca plc Oral Anti-diabetes Drugs Product
Table 59. AstraZeneca plc Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 60. AstraZeneca plc Recent Development
Table 61. Astellas Pharma Inc Company Details
Table 62. Astellas Pharma Inc Business Overview
Table 63. Astellas Pharma Inc Oral Anti-diabetes Drugs Product
Table 64. Astellas Pharma Inc Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 65. Astellas Pharma Inc Recent Development
Table 66. Johnson & Johnson (Janssen Pharmaceuticals) Company Details
Table 67. Johnson & Johnson (Janssen Pharmaceuticals) Business Overview
Table 68. Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Product
Table 69. Johnson & Johnson (Janssen Pharmaceuticals) Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 70. Johnson & Johnson (Janssen Pharmaceuticals) Recent Development
Table 71. Boehringer Ingelheim Company Details
Table 72. Boehringer Ingelheim Business Overview
Table 73. Boehringer Ingelheim Oral Anti-diabetes Drugs Product
Table 74. Boehringer Ingelheim Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 75. Boehringer Ingelheim Recent Development
Table 76. Merck Company Details
Table 77. Merck Business Overview
Table 78. Merck Oral Anti-diabetes Drugs Product
Table 79. Merck Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 80. Merck Recent Development
Table 81. Takeda Company Details
Table 82. Takeda Business Overview
Table 83. Takeda Oral Anti-diabetes Drugs Product
Table 84. Takeda Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 85. Takeda Recent Development
Table 86. Bristol Myers Squibb Company Details
Table 87. Bristol Myers Squibb Business Overview
Table 88. Bristol Myers Squibb Oral Anti-diabetes Drugs Product
Table 89. Bristol Myers Squibb Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 90. Bristol Myers Squibb Recent Development
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Oral Anti-diabetes Drugs Product
Table 94. Novartis Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 95. Novartis Recent Development
Table 96. Pfizer Company Details
Table 97. Pfizer Business Overview
Table 98. Pfizer Oral Anti-diabetes Drugs Product
Table 99. Pfizer Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 100. Pfizer Recent Development
Table 101. Abbott Company Details
Table 102. Abbott Business Overview
Table 103. Abbott Oral Anti-diabetes Drugs Product
Table 104. Abbott Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 105. Abbott Recent Development
Table 106. Biocon Company Details
Table 107. Biocon Business Overview
Table 108. Biocon Oral Anti-diabetes Drugs Product
Table 109. Biocon Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 110. Biocon Recent Development
Table 111. Sunpharma Company Details
Table 112. Sunpharma Business Overview
Table 113. Sunpharma Oral Anti-diabetes Drugs Product
Table 114. Sunpharma Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 115. Sunpharma Recent Development
Table 116. Novo Nordisk Company Details
Table 117. Novo Nordisk Business Overview
Table 118. Novo Nordisk Oral Anti-diabetes Drugs Product
Table 119. Novo Nordisk Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 120. Novo Nordisk Recent Development
Table 121. Piramal Healthcare Company Details
Table 122. Piramal Healthcare Business Overview
Table 123. Piramal Healthcare Oral Anti-diabetes Drugs Product
Table 124. Piramal Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 125. Piramal Healthcare Recent Development
Table 126. Bayer Healthcare Company Details
Table 127. Bayer Healthcare Business Overview
Table 128. Bayer Healthcare Oral Anti-diabetes Drugs Product
Table 129. Bayer Healthcare Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 130. Bayer Healthcare Recent Development
Table 131. Dr. Reddy’s Laboratories Ltd Company Details
Table 132. Dr. Reddy’s Laboratories Ltd Business Overview
Table 133. Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Product
Table 134. Dr. Reddy’s Laboratories Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 135. Dr. Reddy’s Laboratories Ltd Recent Development
Table 136. Glenmark Pharmaceuticals Ltd Company Details
Table 137. Glenmark Pharmaceuticals Ltd Business Overview
Table 138. Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Product
Table 139. Glenmark Pharmaceuticals Ltd Revenue in Oral Anti-diabetes Drugs Business (2020-2025) & (US$ Million)
Table 140. Glenmark Pharmaceuticals Ltd Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
Table 144. Authors List of This Report
List of Figures
Figure 1. Oral Anti-diabetes Drugs Picture
Figure 2. Global Oral Anti-diabetes Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Oral Anti-diabetes Drugs Market Share by Type: 2024 VS 2031
Figure 4. by Type Features
Figure 5. by Drug Class Features
Figure 6. Global Oral Anti-diabetes Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Oral Anti-diabetes Drugs Market Share by Application: 2024 VS 2031
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. Oral Anti-diabetes Drugs Report Years Considered
Figure 12. Global Oral Anti-diabetes Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Oral Anti-diabetes Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Oral Anti-diabetes Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global Oral Anti-diabetes Drugs Market Share by Players in 2024
Figure 16. Global Top Oral Anti-diabetes Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Anti-diabetes Drugs as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Oral Anti-diabetes Drugs Revenue in 2024
Figure 18. North America Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Oral Anti-diabetes Drugs Market Share by Country (2020-2031)
Figure 20. United States Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Oral Anti-diabetes Drugs Market Share by Country (2020-2031)
Figure 24. Germany Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Oral Anti-diabetes Drugs Market Share by Region (2020-2031)
Figure 32. China Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Oral Anti-diabetes Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Oral Anti-diabetes Drugs Market Share by Country (2020-2031)
Figure 44. Turkey Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Oral Anti-diabetes Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Sanofi Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 48. Eli Lilly Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 49. AstraZeneca plc Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 50. Astellas Pharma Inc Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 51. Johnson & Johnson (Janssen Pharmaceuticals) Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 52. Boehringer Ingelheim Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 53. Merck Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 54. Takeda Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 55. Bristol Myers Squibb Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 56. Novartis Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 57. Pfizer Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 58. Abbott Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 59. Biocon Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 60. Sunpharma Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 61. Novo Nordisk Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 62. Piramal Healthcare Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 63. Bayer Healthcare Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 64. Dr. Reddy’s Laboratories Ltd Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 65. Glenmark Pharmaceuticals Ltd Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2020-2025)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global White Oil Market Research Report 2025
Aug 11, 25
Global Piezo Materials Market Research Report 2025
Aug 11, 25
Global Piezoceramic Materials Market Research Report 2025
Aug 11, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232